Mounjaro (tirzepatide) has not been recommended in draft guidance issued by the National Institute for Health and Care Excellence (NICE) on Tuesday for treating 27 June 2023
Data presented in a symposium session at the annual meeting of the European Association for the Study of Diabetes (EASD) provide insights into imeglimin, an inv 18 September 2019
Eisai has presented data showing the potential of its anti-obesity drug Belviq (lorcaserin hydrochloride) to prevent and cause remission of type 2 diabetes. 5 October 2018
Germany’s Boehringer Ingelheim and the USA’s Eli Lilly have presented positive long-term results from the CARMELINA trial at the annual meeting of the European 5 October 2018
Six month Phase II data on Eli Lilly’s dual GIP and GLP-1 receptor agonist, LY3298176, show “clinically meaningful blood sugar reduction and weight loss” in peo 4 October 2018
At EASD 2018, The Pharma Letter spoke with Novo Nordisk’s (NOV: N) chief medical officer Stephen Gough and chief science officer Mads Krogsgaard Thomsen and abo 2 October 2018
London-listed GlaxoSmithKline has presented positive data from the Harmony Outcomes study at the European Association for the Study of Diabetes. 2 October 2018
At its annual meeting in Berlin, the European Association for the Study of Diabetes (EASD) has launched a new initiative, aimed at enabling “the sustainability 2 October 2018
Texan drugmaker Lexicon Pharmaceuticals has announced details of clinical data for oral diabetes therapy sotagliflozin, to be presented at the upcoming annual m 27 September 2018
Adocia has announced details of five abstracts to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.